Dimitrios H Roukos

List of Publications by Year
in descending order

229	7,223	22153	62596
papers	citations	59 h-index	80 g-index

236	236	236	4680
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Meat Intake and Risk of Stomach and Esophageal Adenocarcinoma Within the European Prospective Investigation Into Cancer and Nutrition (EPIC). Journal of the National Cancer Institute, 2006, 98, 345-354.	6.3	301
2	Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPICâ€“EURGAST). International Journal of Cancer, 2006, 118, 2559-2566.	5.1	292
3	The role of heat shock proteins in cancer. Cancer Letters, 2015, 360, 114-118.	7.2	246
4	Perspectives in the treatment of gastric cancer. Nature Clinical Practice Oncology, 2005, 2, 98-107.	4.3	159
5	The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treatment Reviews, 2004, 30, 205-211.	7.7	148
6	Evidence of survival benefit of extended (D2) lymphadenectomy in Western patients with gastric cancer based on a new concept: A prospective long-term follow-up study. Surgery, 1998, 123, 573-578.	1.9	140
7	Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biology and Therapy, 2007, 6, 308-312.	3.4	115
8	Current Advances and Changes in Treatment Strategy May Improve Survival and Quality of Life in Patients With Potentially Curable Gastric Cancer. Annals of Surgical Oncology, 1999, 6, 46-56.	1.5	114
9	Fruit and vegetable intake and the risk of gastric adenocarcinoma: A reanalysis of the european prospective investigation into cancer and nutrition (EPICâ€EURGAST) study after a longer followâ€up. International Journal of Cancer, 2012, 131, 2910-2919.	5.1	114
10	Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nature Clinical Practice Oncology, 2007, 4, 578-590.	4.3	113
11	The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations. Annals of Surgical Oncology, 2008, 15, 21-33.	1.5	108
12	Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance. Annals of Surgical Oncology, 2010, 17, 14-17.	1.5	107
13	Application of microRNAs in diabetes mellitus. Journal of Endocrinology, 2014, 222, R1-R10.	2.6	107
14	Twenty-Oneâ€“Gene Assay: Challenges and Promises in Translating Personal Genomics and Whole-Genome Scans Into Personalized Treatment of Breast Cancer. Journal of Clinical Oncology, 2009, 27, 1337-1338.	1.6	106
15	Personal Genomics and Genome-Wide Association Studies: Novel Discoveries but Limitations for Practical Personalized Medicine. Annals of Surgical Oncology, 2009, 16, 772-773.	1.5	103
16	Individual genomes and personalized medicine: life diversity and complexity. Personalized Medicine, 2010, 7, 347-350.	1.5	100
17	Assessing both genetic variation (SNPs/CNVs) and geneâ€“environment interactions may lead to personalized gastric cancer prevention. Expert Review of Molecular Diagnostics, 2009, 9, 1-6.	3.1	99
18	Novel clinicoâ€“genome network modeling for revolutionizing genotypeâ€–phenotype-based personalized cancer care. Expert Review of Molecular Diagnostics, 2010, 10, 33-48.	3.1	96

#	Article	IF	Citations
19	Mea Culpawith cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Review of Molecular Diagnostics, 2009, 9, 217-221.	3.1	94
20	Human Genetic and Structural Genomic Variation: Would Genome-Wide Association Studies Be the Solution for Cancer Complexity Like Alexander the Great for the â€œGordian Knotâ€?. Annals of Surgical Oncology, 2009, 16, 774-775.	1.5	91
21	Genome-wide association studies: how predictable is a personâ€™s cancer risk?. Expert Review of Anticancer Therapy, 2009, 9, 389-392.	2.4	89
22	Genome-Wide Association Studies and Aggressive Surgery Toward Individualized Prevention, and Improved Local Control and Overall Survival for Gastric Cancer. Annals of Surgical Oncology, 2009, 16, 795-798.	1.5	88
23	Genetics and Personal Genomics for Personalized Breast Cancer Surgery: Progress and Challenges in Research and Clinical Practice. Annals of Surgical Oncology, 2009, 16, 1771-1782.	1.5	87
24	Next-generation, genome sequencing-based biomarkers: concerns and challenges for medicalÂpractice. Biomarkers in Medicine, 2010, 4, 583-586.	1.4	86
25	Distal Gastric Cancer and Extensive Surgery: A New Evaluation Method Based on the Study of the Status of Residual Lymph Nodes After Limited Surgery. Annals of Surgical Oncology, 2000, 7, 719-726.	1.5	84
26	Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Review of Molecular Diagnostics, 2008, 8, 29-39.	3.1	82
27	Is it Time to Change Surgical Strategy for Gastric Cancer in the United States?. Annals of Surgical Oncology, 2004, 11, 727-730.	1.5	81
28	More Controversy than Ever â€“ Challenges and Promises Towards Personalized Treatment of Gastric Cancer. Annals of Surgical Oncology, 2008, 15, 956-960.	1.5	81
29	Early-Stage Gastric Cancer: A Highly Treatable Disease. Annals of Surgical Oncology, 2004, 11, 127-129.	1.5	80
30	Role of surgery in the prophylaxis of hereditary cancer syndromes. Annals of Surgical Oncology, 2002, 9, 607-609.	1.5	79
31	Preventing Breast, Ovarian Cancer in BRCA Carriers: Rational of Prophylactic Surgery and Promises of Surveillance. Annals of Surgical Oncology, 2004, 11, 1030-1034.	1.5	78
32	Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Review of Molecular Diagnostics, 2008, 8, 587-597.	3.1	78
33	Genotypeâ€“phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Review of Molecular Diagnostics, 2010, 10, 541-545.	3.1	78
34	Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics Journal, 2011, 11, 81-92.	2.0	78
35	Genomics and Challenges Toward Personalized Breast Cancer Local Control. Journal of Clinical Oncology, 2008, 26, 4360-4361.	1.6	77
36	Systems medicine: a real approach for future personalized oncology?. Pharmacogenomics, 2010, 11, 283-287.	1.3	77

#	Article	IF	Citations
37	Level I Evidence in Support of Perioperative Chemotherapy for Operable Gastric Cancer: Sufficient for Wide Clinical Use?. Annals of Surgical Oncology, 2007, 14, 2691-2695.	1.5	76
38	From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine. Expert Review of Medical Devices, 2013, 10, 1-6.	2.8	76
39	Extended (D2) Lymph Node Dissection for Gastric Cancer: Do Patients Benefit?. Annals of Surgical Oncology, 2000, 7, 253-255.	1.5	75
40	Perspectives and Risks of Breast-Conservation Therapy for Breast Cancer. Annals of Surgical Oncology, 2003, 10, 718-721.	1.5	75
41	CDH1 Testing: Can it Predict the Prophylactic or Therapeutic Nature of Total Gastrectomy in Hereditary Diffuse Gastric Cancer?. Annals of Surgical Oncology, 2009, 16, 2678-2681.	1.5	75
42	Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Expert Review of Anticancer Therapy, 2009, 9, 1413-1416.	2.4	75
43	Adjuvant chemoradiotherapy in gastric cancer: Wave goodbye to extensive surgery?. Annals of Surgical Oncology, 2002, 9, 220-221.	1.5	74
44	Factors increasing local recurrence in breast-conserving surgery. Expert Review of Anticancer Therapy, 2005, 5, 737-745.	2.4	74
45	Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Review of Anticancer Therapy, 2006, 6, 931-939.	2.4	74
46	Targeting the optimal extent of lymph node dissection for gastric cancer. Journal of Surgical Oncology, 2002, 81, 59-62.	1.7	73
47	Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers ofBRCA1 orBRCA2 mutations. Annals of Surgical Oncology, 2002, 9, 941-943.	1.5	73
48	Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics, 2010, 11, 1039-1043.	1.3	72
49	Breast Cancer Outcomes: The Crucial Role of the Breast Surgeon in the Era of Personal Genetics and Systems Biology. Annals of Surgery, 2009, 249, 1067-1068.	4.2	71
50	Identifying and Preventing High-risk Gastric Cancer Individuals With CDH1 Mutations. Annals of Surgery, 2008, 247, 714-715.	4.2	70
51	A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach. Journal of Cancer Research and Clinical Oncology, 1990, 116, 307-313.	2.5	68
52	Quality of surgery determinant for the outcome of patient with gastric cancer. Annals of Surgical Oncology, 2002, 9, 828-830.	1.5	68
53	Linking contralateral breast cancer with genetics. Radiotherapy and Oncology, 2008, 86, 139-141.	0.6	67
54	From tumor size andHER2status to systems oncology for very early breast cancer treatment. Expert Review of Anticancer Therapy, 2010, 10, 123-128.	2.4	67

#	Article	IF	Citations
55	Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management?. Expert Review of Molecular Diagnostics, 2010, 10, 247-250.	3.1	66
56	Robotic surgery for rectal cancer: may it improve also survival?. Surgical Endoscopy and Other Interventional Techniques, 2008, 22, 1405-1406.	2.4	65
57	Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics, 2011, 12, 695-698.	1.3	61
58	Next-generation sequencing and epigenome technologies: potential medical applications. Expert Review of Medical Devices, 2010, 7, 723-726.	2.8	60
59	Randomized Evidence for Laparoscopic Gastrectomy Short-Term Quality of life Improvement and Challenges for Improving Long-Term Outcomes. Annals of Surgery, 2009, 250, 349-350.	4.2	58
60	Breast-cancer stromal cells with TP53 mutations. New England Journal of Medicine, 2008, 358, 1636; author reply 1636.	27.0	52
61	Laparoscopic Colectomy Survival Benefit for Colon Cancer: Is Evidence From a Randomized Trial True?. Annals of Surgery, 2009, 249, 695-696.	4.2	51
62	Laparoscopic Gastrectomy and Personal Genomics: High-Volume Surgeons and Predictive Biomedicine May Govern the Future for Resectable Gastric Cancer. Annals of Surgery, 2009, 250, 650-651.	4.2	50
63	Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST). Scandinavian Journal of Gastroenterology, 2007, 42, 618-627.	1.5	45
64	Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Review of Anticancer Therapy, 2010, 10, 473-476.	2.4	45
65	Cancer Genome Explosion and Systems Biology: Impact on Surgical Oncology?. Annals of Surgical Oncology, 2011, 18, 12-15.	1.5	45
66	Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer?. Surgical Endoscopy and Other Interventional Techniques, 2008, 22, 1402-1404.	2.4	44
67	Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine. Cancer Treatment Reviews, 2019, 80, 101894.	7.7	37
68	Beyond HER2 and Trastuzumab: Heterogeneity, Systems Biology, and Cancer Origin Research May Guide the Future for Personalized Treatment of Very Early but Aggressive Breast Cancer. Journal of Clinical Oncology, 2010, 28, e279-e280.	1.6	36
69	Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Modern Pathology, 2012, 25, 1055-1068.	5.5	35
70	Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine. Drug Discovery Today, 2017, 22, 1148-1164.	6.4	30
71	Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. New England Journal of Medicine, 2007, 357, 1555-6; author reply 1556.	27.0	30
72	HER2 and response to paclitaxel in node-positive breast cancer. New England Journal of Medicine, 2008, 358, 197; author reply 198.	27.0	30

#	Article	IF	Citations
73	Continuous intraoperative neuromonitoring in thyroid surgery: Safety analysis of 400 consecutive electrode probe placements with standardized procedures. Head and Neck, 2016, 38, E1568-74.	2.0	29
74	Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Review of Medical Devices, 2011, 8, 123-126.	2.8	28
75	Impact of spleen preservation in patients with gastric cancer. Anticancer Research, 2005, 25, 3023-30.	1.1	27
76	Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapy. Drug Discovery Today, 2019, 24, 1281-1294.	6.4	25
77	Chromatin: a key player in complex gene regulation and future cancer therapeutics. Epigenomics, 2011, 3, 395-399.	2.1	23
78	Laparoscopic gastrectomy for gastric cancer: Current evidences. International Journal of Surgery, 2014, 12, 1369-1373.	2.7	22
79	Clinical Cancer Genome and Precision Medicine. Annals of Surgical Oncology, 2012, 19, 3646-3650.	1.5	21
80	Dynamic genome and transcriptional networkâ€based biomarkers and drugs: precision in breast cancer therapy. Medicinal Research Reviews, 2019, 39, 1205-1227.	10.5	21
81	â€˜Bigâ€™ science: genome regulatory networks and novel molecular tools to improve health. Expert Review of Molecular Diagnostics, 2011, 11, 123-126.	3.1	20
82	Disrupting cancer cellsâ€™ biocircuits with interactome-based drugs: is â€˜clinicalâ€™ innovation realistic?. Expert Review of Proteomics, 2012, 9, 349-353.	3.0	20
83	Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks. Expert Review of Anticancer Therapy, 2010, 10, 1187-1195.	2.4	19
84	Translating epigenetics into an anticancer drug pipeline for solid tumors. Expert Review of Medical Devices, 2011, 8, 409-413.	2.8	19
85	Potential of antibody–drug conjugates and novel therapeutics in breast cancer management. OncoTargets and Therapy, 2014, 7, 491.	2.0	19
86	Colorectal cancer: cetuximab,KRAS,BRAF,PIK3CAmutations and beyond. Expert Review of Gastroenterology and Hepatology, 2010, 4, 525-529.	3.0	18
87	Circulating tumor DNA: new horizons for improving cancer treatment. Future Oncology, 2015, 11, 545-548.	2.4	17
88	Bulk and Single-Cell Next-Generation Sequencing: Individualizing Treatment for Colorectal Cancer. Cancers, 2019, 11, 1809.	3.7	17
89	Letters to the Editor. Annals of Surgery, 2000, 232, 719-720.	4.2	17
90	Limitations in Controlling Risk for Recurrence After Curative Surgery for Advanced Gastric Cancer Are Now Well-Explained by Molecular-Based Mechanisms. Annals of Surgical Oncology, 2001, 8, 620-621.	1.5	16

#	Article	IF	Citations
91	Emerging personalized oncology: sequencing and systems strategies. Future Oncology, 2012, 8, 637-641.	2.4	16
92	Clinical relevance of cancer genome sequencing. World Journal of Gastroenterology, 2013, 19, 2011.	3.3	16
93	Crossroad between linear and nonlinear transcription concepts in the discovery of next-generation sequencing systems-based anticancer therapies. Drug Discovery Today, 2016, 21, 663-673.	6.4	16
94	From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. International Journal of Molecular Sciences, 2017, 18, 180.	4.1	16
95	Robotic versus laparoscopic surgery: perspectives for tailoring an optimal surgical option. Expert Review of Medical Devices, 2011, 8, 295-298.	2.8	15
96	Spatiotemporal individual genome codeâ€“lifestyle network: revolutionizing personal diagnostics. Expert Review of Molecular Diagnostics, 2012, 12, 215-218.	3.1	15
97	Research and clinical applications of cancer genome sequencing. Current Opinion in Obstetrics and Gynecology, 2013, 25, 3-10.	2.0	14
98	Biotechnological, genomics and systemsâ€“synthetic biology revolution: redesigning genetic code for a pragmatic systems medicine. Expert Review of Medical Devices, 2012, 9, 97-101.	2.8	13
99	Longevity with systems medicine? Epigenome, genome and environment interactions network. Epigenomics, 2012, 4, 119-123.	2.1	13
100	BMI and lymph node ratio may predict clinical outcomes of gastric cancer. Future Oncology, 2014, 10, 249-255.	2.4	13
101	Novel Next-Generation Sequencing and Networks-Based Therapeutic Targets: Realistic and More Effective Drug Design and Discovery. Current Pharmaceutical Design, 2014, 20, 11-22.	1.9	13
102	PLX4032 and melanoma: resistance, expectations and uncertainty. Expert Review of Anticancer Therapy, 2011, 11, 325-328.	2.4	12
103	Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology. Drug Discovery Today, 2018, 23, 1848-1872.	6.4	12
104	EGFR as a Prognostic Marker for Gastric Cancer. World Journal of Surgery, 2008, 32, 1225-1226.	1.6	11
105	Laparoscopic and Robotic Rectal Cancer Resection: Expectations for Improving Oncological Outcomes. Annals of Surgery, 2010, 251, 185-186.	4.2	11
106	Genome diagnostics: next-generation sequencing, new genome-wide association studies and clinical challenges. Expert Review of Molecular Diagnostics, 2011, 11, 663-666.	3.1	11
107	Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets. Expert Review of Anticancer Therapy, 2013, 13, 5-8.	2.4	11
108	Differential signaling transduction networks for clinical robustness. Expert Review of Proteomics, 2012, 9, 111-114.	3.0	10

#	Article	IF	Citations
109	Assessing tumor heterogeneity and emergence mutations using next-generation sequencing for overcoming cancer drugs resistance. Expert Review of Anticancer Therapy, 2012, 12, 1245-1248.	2.4	9
110	Integrated clinical genomics: new horizon for diagnostic and biomarker discoveries in cancer. Expert Review of Molecular Diagnostics, 2013, 13, 1-4.	3.1	9
111	Intraoperative Neuromonitoring of the External Branch of the Superior Laryngeal Nerve during Thyroidectomy: The Need for Evidence-Based Data and Perioperative Technical/Technological Standardization. Scientific World Journal, The, 2014, 2014, 1-7.	2.1	9
112	Contralateral Prophylactic Mastectomy: Mind the Genetics. Journal of Clinical Oncology, 2008, 26, 1909-1910.	1.6	8
113	Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors. Future Oncology, 2011, 7, 1025-1029.	2.4	8
114	Genome network medicine: innovation to overcome huge challenges in cancer therapy. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2014, 6, 201-208.	6.6	8
115	Circulating free DNA in plasma or serum as biomarkers of carcinogenesis in colon cancer. Future Oncology, 2015, 11, 1455-1458.	2.4	8
116	Fruits and vegetables: do they protect from gastric cancer?. Gastroenterology, 2003, 124, 2006.	1.3	7
117	Targeting VEGF, EGFR, and Other Interacting Pathways for Gastric Cancerâ€"Promises and Reality. Annals of Surgical Oncology, 2008, 15, 2981-2982.	1.5	7
118	Progress, challenges and new genome-based concepts in the multidisciplinary treatment of gastric cancer. Expert Review of Anticancer Therapy, 2011, 11, 503-506.	2.4	7
119	Translating Cancer Genomes Sequencing Revolution into Surgical Oncology Practice. Journal of Surgical Research, 2012, 173, 365-369.	1.6	7
120	Gastric cancer guidelines and genome differences between Japan and the west. Future Oncology, 2013, 9, 1053-1056.	2.4	7
121	Dynamic sequencing of circulating tumor DNA: novel noninvasive cancer biomarker. Biomarkers in Medicine, 2014, 8, 629-632.	1.4	7
122	From standard to new genome-based therapy of gastric cancer. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1023-1026.	3.0	7
123	Advantages of staging laparoscopy in gastric cancer: they are so obvious that they are not evident. Future Oncology, 2015, 11, 369-372.	2.4	7
124	Next-generation sequencing: from conventional applications to breakthrough genomic analyses and precision oncology. Expert Review of Medical Devices, 2018, 15, 1-3.	2.8	7
125	Innovation versus evidence: to trust direct-to-consumer personal genomic tests?. Expert Review of Molecular Diagnostics, 2011, 11, 1-4.	3.1	6
126	Ovarian cancer screening and peritoneal carcinomatosis: standards, â€˜omicsâ€™ and miRNAs for personalized management. Expert Review of Molecular Diagnostics, 2011, 11, 465-467.	3.1	6

#	Article	IF	Citations
127	Totally Laparoscopic Gastrectomy: A Reality for USA and Europe?. Annals of Surgical Oncology, 2009, 16, 2665-2666.	1.5	5
128	Innovative biomarker development for personalized medicine in breast cancer care. Biomarkers in Medicine, 2011, 5, 73-78.	1.4	5
129	Genome network medicine: new diagnostics and predictive tools. Expert Review of Molecular Diagnostics, 2013, 13, 643-646.	3.1	5
130	Tumor heterogeneity-based resistance guides personalized cancer medicine. Future Oncology, 2014, 10, 1889-1892.	2.4	5
131	Identification of novel genes by whole-exome sequencing can improve gastric cancer precision oncology. Future Oncology, 2017, 13, 883-892.	2.4	5
132	Breast and Gastric Cancer: Comparing What We Learn. Annals of Surgical Oncology, 2003, 10, 92-94.	1.5	4
133	Effect of Genetic Cancer Risk Assessment on Surgical Decisions at Breast Cancer Diagnosisâ€"Invited Critique. Archives of Surgery (Chicago, Ill: 1920), 2003, 138, 1329.	1.4	4
134	Surgery in the Era of Gene Expression Profilingâ€"Based Prediction and Individualized, Neoadjuvant Breast Cancer Therapy: The Beginning of the End?. Annals of Surgical Oncology, 2006, 13, 433-435.	1.5	4
135	Can VEGF-D and VEGFR-3 be used as biomarkers for therapeutic decisions in patients with gastric cancer?. Nature Clinical Practice Oncology, 2006, 3, 418-419.	4.3	4
136	Does a new model improve decisions about mismatch-repair genetic testing and Lynch syndrome identification?. Nature Clinical Practice Oncology, 2006, 3, 656-657.	4.3	4
137	HER-2-Negative Breast Cancer Limitations and Next-Generation Sequencing Technology Promises. Annals of Surgical Oncology, 2010, 17, 1720-1720.	1.5	4
138	Cancer genome sequencing and potential application in oncology. Future Oncology, 2010, 6, 1527-1531.	2.4	4
139	Novel cancer drugs based on epigenetics, miRNAs and their interactions. Epigenomics, 2011, 3, 675-678.	2.1	4
140	From traditional molecular biology to network oncology. Future Oncology, 2011, 7, 155-159.	2.4	4
141	Missing heritability, next-generation genome-wide association studies and primary cancer prevention: an Atlantean illusion?. Future Oncology, 2011, 7, 477-480.	2.4	4
142	Targeted therapy: overcoming drug resistance with clinical cancer genome. Expert Review of Anticancer Therapy, 2012, 12, 861-864.	2.4	4
143	Integrative deep-sequencing analysis of cancer samples: discoveries and clinical challenges. Pharmacogenomics Journal, 2013, 13, 205-208.	2.0	4
144	Colorectal liver metastases guidelines, tumor heterogeneity and clonal evolution: can this be translated to patient benefit?. Future Oncology, 2014, 10, 1723-1726.	2.4	4

#	Article	IF	Citations
145	Palbociclib: an approval at last for HER2-negative breast cancer. Future Oncology, 2016, 12, 1097-1100.	2.4	4
146	Intratumor and circulating clonal heterogeneity shape the basis of precision breast cancer therapy. Future Oncology, 2017, 13, 113-116.	2.4	4
147	Proof-of-Concept Pilot Study on Comprehensive Spatiotemporal Intra-Patient Heterogeneity for Colorectal Cancer With Liver Metastasis. Frontiers in Oncology, 2022, 12, 855463.	2.8	4
148	Effectiveness of extended lymphadenectomy in early gastric cancer. Surgery, 1996, 119, 238-239.	1.9	3
149	HER2 and Trastuzumab: Impact of a New Standard Agent on Local Control and Surgery for Breast Cancer. Annals of Surgical Oncology, 2008, 15, 3614-3615.	1.5	3
150	Challenges in Personalizing Decisions on Whole, Partial or No Breast Irradiation and Extent of Surgery for Early Breast Cancer. Annals of Surgical Oncology, 2009, 16, 2656-2657.	1.5	3
151	Totally intracorporeal laparoscopic gastrectomy for gastric cancer. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 3247-3248.	2.4	3
152	Omitting Axilla Lymphadenectomy Even by Positive Sentinel Lymph Node: A Change in Breast Cancer Treatment Practice. Women's Health, 2011, 7, 417-418.	1.5	3
153	New target therapies for patients with neuroendocrine tumors of the pancreas. Expert Review of Gastroenterology and Hepatology, 2011, 5, 563-566.	3.0	3
154	New molecular oncology-changing era: prospects and challenges of cancer genome and integrative systems biology. Expert Review of Anticancer Therapy, 2011, 11, 5-8.	2.4	3
155	Next-generation sequencing-based testing for cancer mutational landscape diversity: clinical implications?. Expert Review of Molecular Diagnostics, 2012, 12, 667-670.	3.1	3
156	Deep sequencing and integrative genome analysis: approaching a new class of biomarkers and therapeutic targets for breast cancer. Pharmacogenomics, 2013, 14, 5-8.	1.3	3
157	Targeted therapy for colorectal cancer resistance to EGF receptor antibodies and new trends. Expert Review of Gastroenterology and Hepatology, 2013, 7, 5-8.	3.0	3
158	Mapping inherited and somatic variation in regulatory DNA: new roadmap for common disease clinical discoveries. Expert Review of Molecular Diagnostics, 2013, 13, 519-522.	3.1	3
159	Head and neck squamous cell carcinoma and human papillomavirus: epidemiology, treatment and future trends. Future Oncology, 2015, 11, 889-891.	2.4	3
160	Targeting dynamics of subclones of GI, liver and pancreatic cancers. Expert Review of Gastroenterology and Hepatology, 2016, 10, 773-776.	3.0	3
161	Novel translational therapeutic strategy by sequencing primary liver cancer genomes. Future Oncology, 2017, 13, 1049-1052.	2.4	3
162	Prediction of pancreatic cancer risk and therapeutic response with next-generation sequencing. Biomarkers in Medicine, 2018, 12, 5-8.	1.4	3

#	Article	IF	Citations
163	Early solid tumor diagnosis through next-generation sequencing of cell-free DNA. Biomarkers in Medicine, 2018, 12, 1197-1201.	1.4	3
164	Primary liver cancer genome sequencing: translational implications and challenges. Expert Review of Gastroenterology and Hepatology, 2017, 11, 875-883.	3.0	3
165	Effectiveness of extended lymphadenectomy in noncurative gastrectomy. American Journal of Surgery, 1996, 172, 303-304.	1.8	2
166	Limitations of Isolated Tumor Cells in Gastric Cancer: Heterogeneity Requests Systems Biology Approaches Towards Personalized Medicine. Annals of Surgical Oncology, 2010, 17, 343-344.	1.5	2
167	Pharmacogenomics for tailoring cardiovascular and anticancer drugs: from genotyping to whole-genome sequencing. Pharmacogenomics, 2011, 12, 1081-1085.	1.3	2
168	Beyond BRCA1/2: polygenic, â€˜polyfunctionalâ€™ molecular circuitry model to predict breast cancer risk. Biomarkers in Medicine, 2013, 7, 675-678.	1.4	2
169	Cancer heterogeneity and signaling network-based drug target. Pharmacogenomics, 2013, 14, 1243-1246.	1.3	2
170	Breakthrough targeted therapeutic approaches to squamous cell carcinoma of the head and neck. Future Oncology, 2015, 11, 9-12.	2.4	2
171	Intratumor heterogeneity: predicting and preventing therapeutic resistance. Biomarkers in Medicine, 2016, 10, 681-684.	1.4	2
172	Breast cancer genome analysis in time and space: biomarker development strategy. Biomarkers in Medicine, 2018, 12, 547-550.	1.4	2
173	Predictive and patient-monitoring biomarkers: precision in the management of colorectal cancer. Biomarkers in Medicine, 2020, 14, 335-339.	1.4	2
174	From personalized to precision cancer medicine. Personalized Medicine, 2020, 17, 245-250.	1.5	2
175	Tumor heterogeneity-driven individualized therapy. Future Oncology, 2021, 17, 235-240.	2.4	2
176	Next-Generation Sequencing in Cancer Epigenomics and Potential Clinical Applications. , 2013, , 31-53.		2
177	SPECIAL DEPARTMENTS. Journal of Clinical Oncology, 2000, 18, 3061-3062.	1.6	1
178	It Is Still Not the Time to Change Surgical Strategy for Gastric Cancer. Annals of Surgical Oncology, 2005, 12, 194-196.	1.5	1
179	Does neoadjuvant versus adjuvant systemic treatment improve outcomes in breast cancer?. Nature Clinical Practice Oncology, 2005, 2, 342-343.	4.3	1
180	Is an aromatase inhibitor more effective than tamoxifen in neoadjuvant endocrine therapy for breast cancer?. Nature Clinical Practice Oncology, 2006, 3, 82-83.	4.3	1

#	Article	IF	Citations
181	Does Lymphadenectomy Improve Survival of Patients with Solid Tumors?. Annals of Surgical Oncology, 2008, 15, 385-385.	1.5	1
182	Increased risk of local recurrence after breast-conserving therapy in young patients. Radiotherapy and Oncology, 2008, 86, 287.	0.6	1
183	Comparative-Effectiveness Research to Standardize Retrieved Nodes for Quality Control in Colorectal Cancer. Annals of Surgery, 2010, 252, 202-203.	4.2	1
184	Quality Control in Colorectal Cancer Care: How Many Lymph Nodes Should Be Harvested?. World Journal of Surgery, 2010, 34, 864-865.	1.6	1
185	Ten Years after Human Genome Sequencing: Is Personalized Breast Screening and Prevention Reality?. World Journal of Surgery, 2010, 34, 2786-2787.	1.6	1
186	Cancer genome sequencing and functional genomics: from translational to clinical medicine. Pharmacogenomics, 2011, 12, 1371-1374.	1.3	1
187	Standards, advances and challenges in laparoscopic total mesorectal excision. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 333-335.	2.4	1
188	Preventing Familial Breast and Ovarian Cancer: Major Research Advances with Little Implication. Women's Health, 2011, 7, 135-138.	1.5	1
189	Gastroesophageal junction carcinoma multimodal treatment: standards, debate and new therapeutic options. Expert Review of Gastroenterology and Hepatology, 2011, 5, 1-4.	3.0	1
190	Personalizing prophylactic surgery in cancer: current practice and future perspectives from new genome-wide association studies. Expert Review of Anticancer Therapy, 2011, 11, 813-816.	2.4	1
191	Novel Wnt signaling and other pathway inhibitors in the colorectal cancer genomic landscape era. Future Oncology, 2012, 8, 1373-1376.	2.4	1
192	Decoding coronary artery disease: somatic mosaicism and genomics for personal and population risk prediction. Biomarkers in Medicine, 2013, 7, 189-192.	1.4	1
193	From targeted monotherapy to combined BRAFâ€“MEK inhibitors and integrated genome analysis for melanoma treatment. Future Oncology, 2013, 9, 5-8.	2.4	1
194	Gene expression â€˜signatureâ€™ limitations and genome architecture-based perspectives for robust cancer biomarkers. Biomarkers in Medicine, 2013, 7, 79-82.	1.4	1
195	From linear â€˜dogmaâ€˜ and trastuzumabâ€“emtansine to future transcriptional circuitry-based drug discovery for breast cancer. Future Oncology, 2014, 10, 145-148.	2.4	1
196	Targeted agents for advanced thyroid cancer: "knowledge is power" â€“ the role of multikinase inhibitors. Future Oncology, 2014, 10, 2099-2102.	2.4	1
197	Regorafenib: a newly approved drug for advanced hepatocellular carcinoma. Future Oncology, 2017, 13, 1665-1668.	2.4	1
198	Genomic heterogeneity: next-generation sequencing enables biomarker identification for hepatocellular carcinoma. Biomarkers in Medicine, 2017, 11, 515-518.	1.4	1

#	Article	IF	Citations
199	Molecular landscape of pancreatic cancer: challenges and clinical implications. Future Oncology, 2017, 13, 2741-2744.	2.4	1
200	Precise predictive and therapeutic strategy for breast cancer. Future Oncology, 2018, 14, 1777-1780.	2.4	1
201	Genomic and transcriptional heterogeneity-based precision in personalized treatment for breast cancer. Personalized Medicine, 2019, 16, 361-364.	1.5	1
202	Precision in cancer pharmacogenomics. Pharmacogenomics, 2020, 21, 311-316.	1.3	1
203	Clinical Proteomics in Cancer Research. Current Proteomics, 2013, 10, 179-191.	0.3	1
204	Letter to the Editor. Annals of Surgery, 1996, 224, 108.	4.2	1
205	Outcomes of breast cancer patients with and without BRCA1/2 mutations. International Journal of Cancer, 2008, 122, 1918-1919.	5.1	0
206	Esophagus and Gastric Cancer: How Surgeonâ€™s Experience and Personal Genomics May Improve Locoregional Control and Survival. World Journal of Surgery, 2009, 33, 161-162.	1.6	0
207	Circulating Cancer Cells: Could They Be Used in the Clinic as Recurrence Markers for Gastric and Colorectal Cancer?. Annals of Surgical Oncology, 2009, 16, 778-779.	1.5	0
208	Magnetic Resonance Imaging and Potential Impact on Extent of Surgery in Breast Cancer. Annals of Surgical Oncology, 2009, 16, 2953-2954.	1.5	0
209	Standardizing Lymphadenectomy for Rectal Cancer. Annals of Surgery, 2010, 252, 569.	4.2	0
210	Caution in Adding Bevacizumab in the Adjuvant Treatment of Breast Cancer. Annals of Surgical Oncology, 2010, 17, 653-654.	1.5	0
211	Thresholds and combined quality control in the multimodal treatment of colorectal cancer. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 1789-1790.	2.4	0
212	New technology-based innovation changes surgical practice and research direction in solid cancers. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 2916-2917.	2.4	0
213	Hope from Japan for esophagogastric cancers: esophagectomy and endoscopic submucosal dissection for gastric tube cancer. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 2924-2925.	2.4	0
214	Improving Women's Health: Advances, Failures and Cancer Genome Prospects. Women's Health, 2010, 6, 769-772.	1.5	0
215	Advances in personalized cancer management. , 2011, , .		0
216	Genome-based diagnostics and predictive tools: a new epoch for breast cancer management. Future Oncology, 2012, 8, 1211-1214.	2.4	0

#	Article	IF	Citations
217	The â€˜sequence everythingâ€™ approach and personalized clinical decision challenges. Expert Review of Molecular Diagnostics, 2012, 12, 319-322.	3.1	0
218	De novomutations, proteinâ€“protein interactions and functional regulatory networks toward novel diagnostics in autism. Expert Review of Proteomics, 2012, 9, 473-476.	3.0	0
219	Dynamics of genome â€˜iPOPâ€™: predicting disease or â€˜narciss-omeâ€™?. Expert Review of Molecular Diagnostics, 2012, 12, 545-548.	3.1	0
220	The Evolution of High-Throughput Sequencing Technologies: From Sanger to Single-Molecule Sequencing. , 2013, , 1-30.		0
221	Network-based drugs: promise and clinical challenges in cardiovascular disease. Expert Review of Proteomics, 2013, 10, 119-122.	3.0	0
222	Bench-top sequencing and clinical implementation: diagnostics and biomarkers challenges. Biomarkers in Medicine, 2014, 8, 221-224.	1.4	0
223	Breakthrough therapies in melanoma. Future Oncology, 2014, 10, 781-784.	2.4	0
224	Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer: What to Avoid. Preliminary Analysis of a Consecutive Series of Patients. Tumori, 2015, 101, 511-516.	1.1	0
225	From traditional to whole-genome sequencing biomarkers for gastric cancer. Biomarkers in Medicine, 2015, 9, 559-562.	1.4	0
226	Precision in personalized prediction-based medicine. Personalized Medicine, 2018, 15, 467-470.	1.5	0
227	Breakthrough cancer genome analysis in time and space: novel oncotargets and early drug development. Pharmacogenomics, 2018, 19, 1303-1310.	1.3	0
228	Precision oncology in patients with nonmetastatic disease: emerging reality or illusion. Future Oncology, 2019, 15, 1805-1810.	2.4	0
229	Targeted Therapy and Novel Agents for the Treatment of Gastric Cancer: A View Toward the Future. , 2015, , 317-330.		0